Stock Groups

Mainz Biomed Rallies After Gaining Exclusive Rights to mRNA Biomarkers -Breaking

by Mike Robinson

[ad_1]

© Reuters.

Sam Boughedda

Investing.com — Mainz Biomed shares rose 40% during Wednesday’s trading. This is a slight decline from the more than doubled levels earlier in the day.

The rally was on the back of news the molecular genetics diagnostic company has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. Access to a range of new mRNA biomarkers.

Access to the portfolio will be used for future integration in ColoAlert (Mainz’s colorectal test). Mainz has the right to licence the global exclusive rights to the five gene expression biomarkers which have been proven effective in diagnosing colorectal carcinoma lesions through the agreement.

ColoAlert, a German-based company is marketing it in Europe via partnerships with third party laboratories. Additionally, the firm is preparing for ColoAlert to be approved in the United States by establishing a regulatory pathway.

Guido Baechler CEI, Mainz Biomed, stated, “Securing the exclusive license for this family novel biomarkers has been a great milestone for our Company. It provides an incredible opportunity to potentially uplift ColoAlert’s technical profile. This could make it one of the most efficient at-home screening tests to detect CRC.”

Mainz stated that it would now start a European clinical study to assess the efficacy of biomarkers.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, futures, indexes and Forex. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]